Mark Heinen is CFO at Better Therapeutics, Inc. (BTTX). They have made 6 open-market trades across 2 companies since 2021, most recently 2026-03-27.
CIK 0001888531
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $193K since 2021, never a sale. Across 6 scored buys the stock is down 17.5% at ninety days, and 14.1 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 50% | 17% |
| Avg Move | -8.7% | -4.7% | -17.5% |
| Alpha | -7.4% | -4.1% | -14.1% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SOAR | BUY | 2024-06-06 | 2024-06-10 | $0.80 | $7K | -35.2% | -33.1% | -41.1% |
| BTTX | BUY | 2022-09-12 | 2022-09-14 | $1.94 | $148K | -11.7% | -20.8% | -25.4% |
| BTTX | BUY | 2022-06-24 | 2022-06-28 | $1.75 | $4K | +3.4% | +14.4% | +0.0% |
| BTTX | BUY | 2022-06-10 | 2022-06-10 | $1.56 | $8K | +20.5% | +15.4% | +18.6% |
| BTTX | BUY | 2022-03-31 | 2022-04-04 | $1.98 | $10K | -31.2% | +5.9% | -18.0% |
| BTTX | BUY | 2021-12-13 | 2021-12-15 | $4.92 | $16K | +1.8% | -10.2% | -39.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.